Organization
PharPoint Research
1 abstract
2 posters
Abstract
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.Org: Medpace Inc, PharPoint Research, SpringWorks Therapeutics,